A Single-Dose, Open-Label, Randomized, Crossover Dose Proportionality Study to Evaluate the Effect of Dose on the Pharmacokinetics of 8, 16, 32 and 64 mg OROS Hydromorphone Under Fasted Conditions in Healthy Adult Taiwanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2014
At a glance
- Drugs Hydromorphone (Primary)
- Indications Pain
- Focus Pharmacokinetics
- 29 Jan 2014 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 09 Dec 2011 New trial record